Cathay Biotech (SH:688065) Xin Lang Cai Jing·2025-08-16 02:32Financial Performance - The company reported a total revenue of 1.671 billion yuan for the first half of 2025 [1] - The net profit attributable to shareholders was 309 million yuan [1] - The net cash inflow from operating activities was 339 million yuan, a decrease of 96.14 million yuan compared to the same period last year, representing a year-on-year decline of 22.08% [1] Key Financial Ratios - The latest debt-to-asset ratio stands at 11.53% [3] - The gross profit margin is reported at 33.85% [3] - The return on equity (ROE) is 1.77%, down by 0.42 percentage points from the same period last year [3] - The diluted earnings per share (EPS) is 0.47 yuan [3] - The total asset turnover ratio is 0.08 times [3] - The inventory turnover ratio is 0.94 times [3] Shareholder Structure - The number of shareholders is 11,700, with the top ten shareholders holding a total of 519 million shares, accounting for 71.97% of the total share capital [3] - The largest shareholder is Shanghai Yaoxiu Biotechnology Partnership (Limited Partnership) with a holding ratio of 35.29% [3] - Other significant shareholders include Shanxi Lu'an Mining Group Co., Ltd. at 7.21% and Cathay Industrial Biotech Ltd. at 6.73% [3]